NovImmune
Company

Last deal

$29.8M

Amount

Series C

Stage

11.01.2016

Date

3

all rounds

$239.06M

Total amount

date founded

Financing round

General

About Company
NovImmune is a biopharmaceutical company that develops therapeutic monoclonal antibodies to treat immune-related disorders.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1998

founders

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

The company's platform focuses on the development of drugs for the treatment of inflammatory diseases, immune-related disorders, and cancer, with a pipeline of preclinical and clinical candidates for validated and novel targets. NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi, and will rebrand as "Light Chain Bioscience - A brand of Novimmune SA". The brand brings to life the research and development of novel multispecific antibodies that rely on their light chain for their function and have a native human structure, making them well-tolerated and easy to develop. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities.
Contacts
Similar Companies
1000
AltruBio

AltruBio

AltruBio is a biopharmaceutical company developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Los Altos, CA, USA

total rounds

5

total raised

$327.61M
Celldex Therapeutics

Celldex Therapeutics

Celldex develops antibodies to treat diseases with inadequate treatments.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Hampton, NJ 08827, USA

total rounds

8

total raised

$1.48B
Cincera Therapeutics

Cincera Therapeutics

Cincera Therapeutics is a biotechnology company developing drugs to treat metabolic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Dandenong Rd, Melbourne VIC, Australia

total rounds

3

total raised

$7.04M
Cytonus Therapeutics

Cytonus Therapeutics

Cytonus Therapeutics is a San Diego biotech company focused on cell-based drug delivery for immune-oncology and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

6

total raised

$5.68M

Financials

Funding Rounds
10
3

Number of Funding Rounds

$239.06M

Money Raised

Their latest funding was raised on 11.01.2016. Their latest round Series C

Date 
Funding Round 
Investors 
Money Raised 
Lead 
11.01.2016
$29.8M
15.10.2012
$7.77M
Local Amount - EUR 6M
Rosetta Capital

Rosetta Capital

Rosetta Capital Limited is a London-based private equity and venture capital firm focused on direct secondary investments.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

Location

London, UK

count Of Investments

13
Co-Investors
Investors
9
2

Number of lead investors

9

Number of investors

Investor 
Lead 
Round 
Partners 
No
Venture - Series Unknown
Yes
Series B, Venture - Series Unknown
No
Series B, Venture - Series Unknown
Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund is a private equity and venture capital arm of Novartis AG.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Basel, Switzerland

count Of Investments

201

count Of Exists

39
BZ Bank

BZ Bank

BZ Bank is a Wiler-based banking firm that specializes in investing in early stage and later stage ventures.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Venture Capital, Banking

Location

Wiler, 4252 Bärschwil, Switzerland

count Of Investments

5
Aravis Ventures

Aravis Ventures

Aravis Ventures is a private equity firm that invests in renewable energy and life sciences sector.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Biotechnology, Financial Services, Venture Capital

Location

Zürich, Switzerland

count Of Investments

22

count Of Exists

8
Bernard Mach

Bernard Mach

Founder of Novimmune, and former professor and director of the Department of Genetics and Microbiology, Faculty of Medicine, University of Geneva, Bernard Mach is the inventor of cDNA cloning and is specialized in the molecular biology of immune response genes. Bernard was co-founder and member of the SAB of Biogen (1978-1992). He was Chairman of the Lombard Odier Immunology Fund Scientific Advisory Board from 1994 to 2002. Former member of the Board of Directors of Serono and former board member of Lonza as well as Scientific Advisor to various institutes and companies. He was a Member of the Swiss Science Council (1974-1984), is a special member of the Swiss Academy of Medical Sciences and is a Member of the French Academy of Sciences. He is now Chairman of the SAB of Aravis Venture Associates.

current job

NovImmune
NovImmune

People

Founders
1
Bernard Mach
Bernard Mach

Bernard Mach

Founder of Novimmune, and former professor and director of the Department of Genetics and Microbiology, Faculty of Medicine, University of Geneva, Bernard Mach is the inventor of cDNA cloning and is specialized in the molecular biology of immune response genes. Bernard was co-founder and member of the SAB of Biogen (1978-1992). He was Chairman of the Lombard Odier Immunology Fund Scientific Advisory Board from 1994 to 2002. Former member of the Board of Directors of Serono and former board member of Lonza as well as Scientific Advisor to various institutes and companies. He was a Member of the Swiss Science Council (1974-1984), is a special member of the Swiss Academy of Medical Sciences and is a Member of the French Academy of Sciences. He is now Chairman of the SAB of Aravis Venture Associates.

current job

NovImmune
NovImmune

Bernard Mach

Employee Profiles
26

Oliver Eckelmann

Chief operations officer and cfo, secretary to the board of directors

Ricardo Azedo

Senior clinical data manager

Erik Trock-Jansen

Erik Trock-Jansen

CEO

Mireille Guerrier

Research assistant

Sven Zimmermann

Sven Zimmermann

CFO

Andrew Oakley

Andrew Oakley

CFO

Adrian Mills

Adrian Mills

Chief Business Officer/Chief Commercial Office

Nicolas Fischer

Head of research department sa

Activity

Recent News
1